221 Crescent Street
Building 17 Suite 102b
Waltham, MA 02453
United States
650-394-5230
https://www.apogeetherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 91
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Apogee Therapeutics, Inc.’s ISS governance QualityScore as of 1 June 2024 is 8. The pillar scores are Audit: 6; Board: 5; Shareholder rights: 9; Compensation: 9.